Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
Mark Crowther, Distinguished University Professor and Chair, Department of Medicine at McMaster University, shared on LinkedIn:
”McMaster’s Department of Medicine: New Insight into a Life-Threatening Blood Disorder, Led by McMaster Researchers
A paper published last week in the New England Journal of Medicine has reshaped how we understand heparin-induced thrombocytopenia (HIT)—a serious reaction to a widely used blood thinner.
Researchers from McMaster Faculty of Health Sciences and the McMaster University Department of Medicine have found that, contrary to decades of belief, a single monoclonal antibody is responsible for triggering HIT.
This key discovery suggests the condition is not a polyclonal immune response, as previously thought, but rather driven by one dominant antibody—an insight that could significantly improve diagnostic precision and lead to more targeted therapies.
The study was led by Dr. Ishac Nazy, PhD, Professor in the Department of Medicine and John G. Kelton Chair in Immunological Blood Disorders and and Dr Donald Arnold.
Their team includes investigators from the McMaster Platelet Immunology Laboratory and the Michael G. DeGroote Centre for Transfusion Research.
Dr. Nazy notes: ‘Our findings correct a long-standing misunderstanding of HIT and point toward more accurate and safer testing methods.’
This work underscores McMaster’s continued leadership in translational research—bringing molecular discoveries closer to clinical application.”
Find more insights here.
Stay updated on the emerging in the field of platelet disorders with Hemostasis Today.
-
Feb 16, 2026, 06:21C. Michael Gibson: Favorable Safety Outcomes With Asundexian
-
Feb 16, 2026, 06:18Jecko Thachil: What Do Clinicians Mean by “Coagulopathy”?
-
Feb 16, 2026, 06:04Inside 2026 Highlights of ASH in the Mediterranean, Middle East, and North Africa with Dr. Heghine Khachatryan
-
Feb 15, 2026, 10:56Don’t Miss PNH: Clinical Practice From ISTH – Medscape
-
Feb 15, 2026, 10:52Awareness and Research on Factor V Deficiency Are Critical – EHC
-
Feb 15, 2026, 10:43Peter Zdziarski: Protecting Patient Data in the Rare Disease Community
-
Feb 15, 2026, 10:31Michiel Voet: The Price Tag of a Whole Blood Strategy
-
Feb 15, 2026, 10:26Sifat Jubaira: K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy
-
Feb 15, 2026, 09:29Gevorg Tamamyan: Childhood Cancer is Curable. Inequity Is Not